Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$470.18 USD
+14.84 (3.26%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $470.45 +0.27 (0.06%) 6:56 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Brokerage Reports
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 281 - 300 ( 326 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Better than Expected Results with VX-770
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Upgrading to Relative OUTPERFORM and Raising PT to $51
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals - Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Potential Q1:11 Movers
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Anticipating Telaprevir Launch in May - Raising Target Price from $45 to $48
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Raising PT to $42 on Increasing Pricing of CF Franchise; Q4:10 Earnings Uneventful; Multiple Milestones in H1:11
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of January 23
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Interim ASPIRE Data of TMC435 Encouraging
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Plans to Evaluate Three-Drug All-Oral Regimen
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Upcoming Events for the Week of October 24
Provider: WEDBUSH SECURITIES INC.